The Prader-Willi Syndrome (PWS) drugs in development market research report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Prader-Willi Syndrome (PWS). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued products.
GlobalData tracks 26 drugs in development for Prader-Willi Syndrome (PWS) by 25 companies/universities/institutes. The top development phase for Prader-Willi Syndrome (PWS) is preclinical with ten drugs in that stage. The Prader-Willi Syndrome (PWS) pipeline has 23 drugs in development by companies and three by universities/ institutes. Some of the companies in the Prader-Willi Syndrome (PWS) pipeline products market are: Harmony Biosciences, Aardvark Therapeutics and ERX Pharmaceuticals.
The key targets in the Prader-Willi Syndrome (PWS) pipeline products market include Oxytocin Receptor, Histamine H3 Receptor, and Growth Hormone Secretagogue Receptor Type 1.
The key mechanisms of action in the Prader-Willi Syndrome (PWS) pipeline product include Oxytocin Receptor Agonist with six drugs in Filing rejected/Withdrawn. The Prader-Willi Syndrome (PWS) pipeline products include seven routes of administration with the top ROA being Oral and four key molecule types in the Prader-Willi Syndrome (PWS) pipeline products market including Small Molecule, and Synthetic Peptide.
Prader-Willi Syndrome (PWS) overview
Prader-Willi syndrome (PWS) is a rare congenital genetic disorder that results in a number of physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In the majority of cases, there is a deletion. In the remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15’s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones, and a constant feeling of hunger.
For a complete picture of Prader-Willi Syndrome (PWS)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
